Orion PharmaDHA:ORIONPHARM 71 9-Day RSI is 53.12 as of Jul. 06, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.26 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 552 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 72.64% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-06), Orion Pharma's 9-Day RSI is 53.12.
The industry rank for Orion Pharma's 9-Day RSI or its related term are showing as below:
DHA:ORIONPHARM's 9-Day RSI is ranked worse than 72.64% of 552
companies
in the Utilities - Independent Power Producers industry
Industry Median: 43.56
vs DHA:ORIONPHARM: 53.12
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Orion Pharma 9-Day RSI Related Terms
DHA:ORIONPHARM vs CEG, VST, NRG: 9-Day RSI Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma 9-Day RSI vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Orion Pharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a 9-Day RSI of 53.12 as of Jul. 06, 2026. According to the industry distribution chart, Orion Pharma ranks #401 out of 552 companies in the Utilities - Independent Power Producers industry, placing it in the top 72.6%.
Is Orion Pharma's 9-Day RSI too high?
Orion Pharma's current 9-Day RSI is 53.12. The Utilities - Independent Power Producers industry median 9-Day RSI is 43.56. Orion Pharma's value of 53.12 is 21.9% above this industry median. Based on the distribution chart, Orion Pharma ranks #401 out of 552 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's 9-Day RSI compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #401 out of 552 companies for 9-Day RSI. This places Orion Pharma in the lower half of its industry. The industry median 9-Day RSI is 43.56. Orion Pharma's value of 53.12 is 21.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for an Utilities - Independent Power Producers company?
The median 9-Day RSI among Utilities - Independent Power Producers companies is 43.56, based on 552 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current 9-Day RSI of 53.12 is 21.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Utilities - Independent Power Producers industry, the median 9-Day RSI is 43.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current 9-Day RSI is 53.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.26, compared to a current price of BDT28.30 — trading 39.7% above its estimated fair value. The current 9-Day RSI is 53.12 and 21.9% above the Utilities - Independent Power Producers industry median of 43.56. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current 9-Day RSI is 53.12 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.30 is trading 39.7% above its estimated GF Value™ of BDT20.26.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
9-Day RSI: 53.12
GF Value™: BDT20.26 vs. price of BDT28.30 (39.7% above fair value)
Industry Position: 21.9% above the Utilities - Independent Power Producers median (#401 of 552)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 